Greek university bridging advanced materials science and biomedical engineering, with growing strength in cardiovascular modelling and eldercare technology.
The University of Ioannina is a broad-based Greek research university with particular depth in biomedical engineering, health informatics, and advanced materials. Their teams develop computational models for cardiovascular disease, build mHealth platforms for chronic disease management, and work on graphene-based composites and smart structural materials. They also contribute to clinical data harmonization for rare and autoimmune diseases, and have growing activity in eldercare technology and personalized nutrition.
Projects like TAXINOMISIS (carotid artery stratification), SILICOFCM (cardiac drug modelling), InSilc (BVS design), PD_manager, OPERAM, and COMPAR-EU demonstrate sustained focus on computational and clinical approaches to chronic disease.
Participation in GrapheneCore1/2, SELECTA (smart alloys), InnoSMART (shape memory alloys), AIRPOXY (smart epoxy composites), HARVEST (multifunctional composites), and CORNET (organic electronics) shows deep materials science capability.
HarmonicSS (Sjögren syndrome cohort harmonization), ImmunAID (autoinflammatory disorders), and COMPAR-EU (self-management interventions) involve large-scale clinical data mining and cross-cohort analysis.
HOLOBALANCE (hologram-based balance rehabilitation, coordinated), plus recent keyword clusters around dignity in care, caring science, and elder engagement with technology indicate a growing research line.
MAT4TREAT and AQUAlity focus on nanofiltration and novel materials for removing emerging contaminants from water, supported by materials expertise from the composites portfolio.
Stance4Health (personalized nutrition via gut microbiota) and INCREdible (Mediterranean non-wood forest products) extend their health expertise into food and agriculture.
In the early H2020 period (2014–2018), the University of Ioannina focused heavily on fundamental materials science — graphene, shape memory alloys, smart coatings — alongside initial health informatics projects like PD_manager and HarmonicSS. From 2018 onward, their portfolio shifted decisively toward biomedical engineering, clinical decision support, and patient stratification (TAXINOMISIS, SILICOFCM, ImmunAID), while a new thread emerged around eldercare, dignity in care, and technology for ageing populations. The materials work continued but became more application-oriented, moving into aerospace composites (AIRPOXY, HARVEST) and organic electronics (CORNET).
Moving from fundamental materials research toward health technology applications, with a growing emphasis on computational medicine, patient stratification, and dignified ageing — making them an increasingly relevant partner for digital health and medtech consortia.
The University of Ioannina primarily operates as an active research partner, joining established consortia (39 of 49 projects as participant) rather than leading them. However, their 9 coordinator roles — including substantive projects like TAXINOMISIS (€760K), HARVEST (€795K), and HOLOBALANCE (€654K) — show they can and do lead when the topic aligns with their core strengths. With 839 unique partners across 43 countries, they are a well-connected hub in the European research landscape, comfortable in both large flagships (Graphene, EUROfusion) and focused clinical consortia.
With 839 unique consortium partners spanning 43 countries, the University of Ioannina has one of the broader collaboration networks among Greek universities, anchored in Southern and Western European health and materials research communities.
What distinguishes the University of Ioannina is their ability to bridge advanced materials science and biomedical engineering — a combination that is relatively rare among Greek universities. Their HARVEST project, for example, combines thermoelectric composites with structural health monitoring, while TAXINOMISIS merges computational modelling with clinical stratification for vascular disease. For consortium builders, this cross-disciplinary range means one partner can cover both the materials development and the clinical validation workpackages.
